News
Entropy Neurodynamics Granted Australian Patent for TRP8803 to Treat Chronic Pain and Psychiatric Conditions
1+ mon, 4+ day ago (478+ words) AU patent granted for TRP8803 therapy. Two-phase IV dosing with rapid onset and stop. Protection across routes to 2042. Entropy Neurodynamics (ASX: ENP) has been granted an Australian patent covering lead asset TRP8803 developed as a precision-controlled method of administering psilocybin, psilocin and…...
Paradigm Biopharmaceuticals Publishes Canine Osteoarthritis Study Showing Durable PPS Benefits
1+ mon, 4+ day ago (491+ words) Paradigm Biopharmaceuticals (ASX: PAR) reports durable 26-week canine OA PPS benefits in peer-reviewed PLOS One, bolstering translational human OA potential. PPS: durable pain relief to 26 weeks Gait improved; symmetry near normal at 8-26 wks MRI: cartilage stabilised; minor gains Canine OA…...